---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-045370"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:59:04.938094+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ionis Q3 revenue $134M (-7% YoY); reaffirms 2024 P&L guidance; increases cash guidance to $2.2B

## Summary
- Q3 total revenue $134M vs $144M YoY; commercial revenue $76M, R&D revenue $58M.
- WAINUA royalty revenue $5M in Q3 ($10M YTD); SPINRAZA royalties $57M in Q3 ($152M YTD).
- Olezarsen PDUFA Dec 19, 2024 for FCS; donidalorsen PDUFA Aug 21, 2025 for HAE.
- Cash & investments $2.5B at Sep 30; raised ~$500M from 11.5M-share offering at $43.50.
- Phase 3 ION582 for Angelman syndrome to begin H1 2025 after positive FDA end-of-Phase 2 meeting.

## SEC filing metadata
- accession: 0001140361-24-045370
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036124045370/0001140361-24-045370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036124045370/ef20038192_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-045370
- JSON: https://secwatch.observer/filing/0001140361-24-045370.json
- Plain text: https://secwatch.observer/filing/0001140361-24-045370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.